RAC - Charts & Price Action, page-25889

Let me correct a typo (adding a missing word from my earlier post)!

"... And here’s the irony: the very fact that RC220 no longer crystalizes - the property that sets it apart - might actually allow it to do something ELSE instead. Hopefully that something is good. But it could be bad. That’s why testing is still essential. A formulation change can open doors or landmines..."

I agree with the "... final kicker - what if Race is able to find some major use for RC220 that is unexpected from the historical trials ...." ever suggested!

[IF you do not like speculation - LOOK AWAY NOW]. Here’s my theoretical take:

It is quite feasible that the absence of crystallisation (improved solubility) might do more than the eye can currently see — it might actually release the molecule, allowing it to do things it couldn’t before. That might include reaching tissues it couldn’t access, interacting with new targets, or unlocking entirely new mechanisms.That possibility is very real. Thats why I don’t view RC220 as a “box-ticking RC110 2.0,” but as a potential next-generation anthracycline in its own right.

And DT knows the MOA, so when he hints at “unexpected benefits,” I think its worth noting!

I am leaning on the aging lane, as we have been told about it officially! But is it just anti-chemo-induced accelerated aging, or could it extend to cancer itself (cancer induced accelerated aging is real - its why patients are frail before touching chemo), or even more general aging processes? With the molecule released, what might it do to one's aging brain cells, bones, joints, and other bits not safe to discuss in a family friendly forum …!

Who would've thought GLP-1s would turn out to help with diabetes, obesity, heart disease, kidney protection, and maybe even Alzheimer’s?Could RC220 surprise us in the same way?Just maybe... it’s Bisantrene’s time.

END of my SPECULATION - DYOR!